WHO should:

1. Continue to serve as a platform for the exchange of information on important regulatory decisions of worldwide implication.

2. Take measures to reinforce the collaboration between drug regulatory and criminal investigation authorities internationally, in particular Interpol and the World Customs Organization, to deal with criminal activities involving pharmaceutical products and materials.

3. Implement recommendations on safe trade and control of starting materials as set out in document WHO/PHARM/98.605, including risk assessment of starting materials.

4. Develop safe trading practices in close collaboration with brokers, traders and other international organizations and institutions.

5. Support training of assessors for new drug applications and good manufacturing practice (GMP) inspectors in countries with limited resources, in collaboration with national health authorities.

Countries should:

6. Establish a structure to facilitate close collaboration between the regulatory authority granting marketing authorizations for pharmaceuticals and inspection bodies.

7. Develop a plan for implementation of drug regulation, and monitor progress.

8. Implement quality systems for pharmaceuticals that are also appropriate to starting materials intended for export.